- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01418742
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Phase II Trial of Skin Toxicity Treatment in Subjects With Advanced or Metastatic Colorectal Carcinoma Receiving Panitumumab
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Because of their frequency and severity panitumumab associated skin toxicities affect patients' quality of life and thus threaten patients' compliance to therapy. There is an urgent need for evidence-based treatment recommendations for the prevention and management of panitumumab -associated skin toxicities.
The study aims to compare the efficacy and safety of a manageable preemptive treatment with oral doxycycline in combination with a supportive topical regimen containing erythromycin cream (2 %) over duration of 12 weeks on the occurrence and grade of panitumumab induced skin toxicities in a double-blind, controlled randomized setting. Basic skin treatment with or without doxycycline will be discontinued at the end of study treatment after 12 weeks or until a value of 6-10 is observed on the visual analogue scale (VAS), whichever is sooner.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 12559
- DRK Kliniken Berlin / Köpenick, Klinik für Chirurgie
-
Berlin, Germany, 13055
- Onkologische Schwerpunktpraxis
-
Berlin, Germany, 13347
- Medizinisches Versorgungszentrum Ärzteforum Seestraße
-
Berlin, Germany, 13355
- Charité Campus Virchow Klinikum (CVK), Centrum für Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie u. Onkologie
-
Bernau, Germany, 16321
- Ärzteforum Bernau
-
Brandenburg, Germany, 14770
- Onkologische Schwerpunktpraxis
-
Dessau, Germany, 06847
- Städtisches Klinikum Dessau, Hömatologie und Internistische Onkologie
-
Eisenach, Germany, 99817
- St. Georg Klinikum Eisenach gGmbH, Klinik für Innere Medizin 2
-
Halle, Germany, 06110
- Krankenhaus St. Elisabeth u. St. Barbara, Klinik für Allgemein- u. Visceralchirurgie
-
Hennigsdorf, Germany, 16761
- Ärzteforum Hennigsdorf
-
Jena, Germany, 07743
- eps-early phase GmbH
-
Quedlinburg, Germany, 06484
- Klinikum Dorothea Christiane Erxleben Quedlinburg gGmbH, Klinik f. Allgemein, Vizeral- und Gefäßchirurgie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with advanced or metastatic colorectal cancer (mCRC) and non-mutated (wild-type) KRAS who are planned to receive treatment with panitumumab monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens and without prior treatment with epidermal growth factor receptor (EGFR) antibody
- Man or woman 18 years of age or older
- Signed and dated informed consent before the start of specific protocol procedures
- ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1, or 2
- Bilirubin ≤ 1.5 x ULN, SGOT/SGPT ≤ 2.5 x ULN, AP ≤ 3 x ULN if no evidence of liver metastases or Bilirubin ≤ 3 x ULN, SGOT/SGPT ≤ 5 x ULN, AP ≤ 5 x ULN if evidence of liver metastases
- Women of child-bearing potential have to use adequate highly effective methods of contraception . Since doxycyline may reduce efficacy of hormonal contraceptives, women of child-bearing potential have to use double-barrier methods within 4 weeks before first intake of study medication, during study participation and at least 6 weeks after last intake of study medication even if using hormonal contraceptives Women are considered to be of child-bearing potential unless they are ≥ 50 years old and for more than 2 years amenorrheic or unless they are surgically sterile.
Exclusion Criteria:
- Absence of any of the above-listed inclusion criteria
- Any serious medical condition or psychiatric illness that would interfere with the patient's ability to sign the informed consent form.
- Allergic reaction to one of the medications to be used
- Subject allergic to panitumumab or any components of the panitumumab formulation or treatment regimen
- Prior treatment with EGFR antibody
- CYP3A4 enzyme inducers, inhibitors, and substrates (eg, phenytoin, phenobarbital, carbamazepine, ketoconazole, rifampicin, rifabutin, and St. John's Wort) ≤ 2 weeks before randomization (itraconazole should be used with caution)
- Subjects with hypersensitivity to doxycycline, other tetracyclines, or ingredients of doxycycline capsules
- Systemic treatment with antibiotics which was completed less than 7 days prior to randomization
- Pregnant and/or breast-feeding women
- Active participation in other clinical studies in the previous 4 weeks
- Serious liver function disorders
- History of, or evidence of, interstitial pneumonitis or pulmonary fibrosis
- Person who has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Doxycycline 100 mg BID oral use
|
comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
|
PLACEBO_COMPARATOR: Placebo 100 mg BID oral use
|
mCRC patients receiving panitumumab as EGFR inhibitor.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time until unblinding of skin therapy allocation (basic skin treatment with or without doxycycline) due to insufficient efficacy (i.e. unbearable skin toxicity, measured by patient's allocating point 6 through 10 on a visual analogue scale)
Time Frame: 30 month
|
30 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of specific ≥ grade 2 skin toxicities over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner
Time Frame: 30 months
|
30 months
|
Time to first occurrence of specific ≥ grade 2 skin toxicities
Time Frame: 30 months
|
30 months
|
Most severe specific ≥ grade 3 skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner
Time Frame: 30 months
|
30 months
|
Time to the first most severe specific ≥ grade 3 skin toxicities
Time Frame: 30 month
|
30 month
|
Incidence of panitumumab dose reduction due to the specific skin toxicities of interest over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner
Time Frame: 30 month
|
30 month
|
Scores in DLQI under preemptive basic skin treatment with or without doxycycline
Time Frame: 30month
|
30month
|
Incidence of doxycycline related adverse events
Time Frame: 30 month
|
30 month
|
Type of panitumumab related adverse events
Time Frame: 30 month
|
30 month
|
Response rate to panitumumab over 12 weeks or until a value of 6-10 is observed on the VAS, whichever is sooner (only if patient received at least 8 weeks of study treatment)
Time Frame: 30 month
|
30 month
|
Type of doxycycline related adverse events
Time Frame: 30 month
|
30 month
|
Severity of doxycycline related adverse events
Time Frame: 30 month
|
30 month
|
Incidence of panitumumab related adverse events
Time Frame: 30 month
|
30 month
|
Severity of panitumumab related adverse events
Time Frame: 30 month
|
30 month
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Hanno Riess, Prof., Charité Campus Virchow Klinikum, Klinik für Innere Medizin mit Schwerpunkt Hämatologie u. Onkologie
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Carcinoma
- Colorectal Neoplasms
- Anti-Infective Agents
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Doxycycline
- Panitumumab
Other Study ID Numbers
- GMIHO-010/2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal CarcinomaUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Roswell Park Cancer InstituteNot yet recruitingPembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Wuhan Union Hospital, ChinaNot yet recruitingRecurrent Colorectal Carcinoma | Advanced Colorectal CarcinomaChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Carcinoma | Colorectal Adenoma and CarcinomaNetherlands
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Center for Advancing Translational Sciences (NCATS)Not yet recruitingRecurrent Colorectal Carcinoma | Locally Advanced Colorectal Carcinoma | Stage III Colorectal CancerUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
Clinical Trials on Panitumumab, Doxycycline/Placebo
-
Thomas GardnerJuvenile Diabetes Research FoundationCompleted
-
Felix Chikita Fredy, MDNational Cardiovascular Center Harapan Kita Hospital IndonesiaUnknownHeart Failure | ST Elevation Myocardial Infarction | Anterior Wall Myocardial Infarction | Remodeling, VentricularIndonesia
-
International Centre for Diarrhoeal Disease Research...CompletedCOVID-19 PatientsBangladesh
-
University Hospital Inselspital, BerneTerminatedBladder Pain Syndrome | Chronic Pelvic Pain SyndromeSwitzerland
-
University of California, San FranciscoCompletedArteriovenous Malformations | Cavernous Angiomas | Brain AneurysmsUnited States
-
Warner ChilcottCompleted
-
University of Alabama at BirminghamRecruiting
-
Hospital General de MexicaliRecruitingRocky Mountain Spotted FeverMexico
-
University Medical Centre LjubljanaCompleted
-
The Task Force for Global HealthUnited States Agency for International Development (USAID)CompletedLymphedema | Lymphatic Filariasis | FilariasisIndia